AcquisitionOther
Concentra Biosciences acquired Kronos Bio
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Concentra Biosciences -> Kronos Bio · $0.57 per share
Merger agreement to acquire Kronos Bio focusing on development of small molecule therapeutics for cancer and autoimmune diseases.
Open source record (SEC) ↗